Uncategorized

Ipsen sends clear Memo to rare diseases with up to $796M buyout

Published

on

Ipsen is penning its second acquisition of the week, this time securing Memo Therapeutics and its midstage monoclonal antibody in a deal that could approach $800 million.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version